Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Marshall Edwards -- MSHL -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (8)	9/15/2005 7:00:13 PM
From: tuck	Read Replies (2) \| Respond to of 26

>>The Company believes that it will have sufficient cash resources to fund existing operations at least through the end of June 2006 and to complete the current Phase I and lb/IIa clinical trial program. The Company is currently planning to conduct a pivotal clinical study to support marketing approval of phenoxodiol for ovarian cancer. The trial will use phenoxodiol in combination with carboplatin and will assess phenoxodiol's efficacy for late stage ovarian cancer patients who are refractory to standard chemotherapies. The Company is discussing trial design with the FDA to develop a trial protocol, including the number of treatment arms needed to be completed and the number of patients required to be tested in each arm. The Company is still in the planning stage of the trial design and has not determined the cash resources needed to complete the trial. Also, additional cash resources may be required if a new cancer compound is developed by Novogen and the Company secures a license under the terms of the Company's license option deed from Novogen. Novogen has notified the Company that its new anti-cancer compound NV-196 (previously referred to as NV-18) is now an "option compound" under the terms of the license option deed and that Novogen has commenced Phase I clinical trials. The Company has commissioned an independent report on NV-196 and will review initial clinical results before making a decision to commence license negotiations with Novogen.<< From the 10-K filed yesterday. Wonder if the recent weakness is speculation that the company will inlicense and increase burn. If so, it'll probably have to finance even sooner. Say, were you able to get a bid and ask for the warrants when you traded them? They seem to trade so little now that putting a market value on them is hard. Probably the stock itself is the better risk now. Cheers, Tuck